used for concurrent CRT, including cisplatin/etoposide, carboplatin/paclitaxel, cisplatin/vinblastine, and, for nonsquamous pathology, carboplatin or cisplatin with pemetrexed. 7 The carboplatin/paclitaxel regimen is given weekly with radiation therapy
Search Results
Dipesh Uprety and David E. Marinier
Louis Burt Nabors
complete all of the prescribed cycles of chemotherapy,” revealed Dr. Nabors. Based on the findings of both RTOG 9402 and EORTC 26951, the adjuvant treatment pathway in the 2015 NCCN Guidelines for CNS Cancers hinges on the pathology results of the
Grant A. McArthur
. Chromogenic in situ hybridization and FISH in pathology . Methods Mol Biol 2002 ; 204 : 343 – 351 . 8. Haycox CL Odland PB Olbricht SM Piepkorn M . Immunohistochemical characterization of dermatofibrosarcoma protuberans with practical
David A. Kooby and Daniel G. Coit
the gastric cancer study in surgery and pathology. I. Clinical classification . Jpn J Surg 1981 ; 11 : 127 – 139 . 38 Soga J Kobayashi K Saito J . The role of lymphadenectomy in curative surgery for gastric cancer . World J Surg 1979
Damien Urban, Danny Rischin, Christopher Angel, Ieta D’Costa, and Benjamin Solomon
Classification of Tumours. Pathology and Genetics of Head and Neck Tumours . Lyon, France : IARC Press ; 2005 . 2. Wang YL Zhu YX Chen TZ . Clinicopathologic study of 1176 salivary gland tumors in a Chinese population: experience of one cancer
Jonathan R. Strosberg, Gary D. Hammer, and Gerard M. Doherty
Edited by Kerrin G. Robinson
revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors . Am J Surg Pathol 2002 ; 26 : 1612 – 1619 . 34 DeLellis RA Lloyd RV Heitz PU Eng C , eds. World Health Organization Classification of Tumours: Pathology
William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Janice Lyons, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena S. Moran, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda L. Telli, John H. Ward, Rashmi Kumar, and Dorothy A. Shead
developed by a multidisciplinary panel of representatives from NCCN Member Institutions with breast cancer–focused expertise in the fields of medical, surgical, and radiation oncology and pathology, reconstructive surgery, and patient advocacy. This
David S. Ettinger, Dara L. Aisner, Douglas E. Wood, Wallace Akerley, Jessica Bauman, Joe Y. Chang, Lucian R. Chirieac, Thomas A. D'Amico, Thomas J. Dilling, Michael Dobelbower, Ramaswamy Govindan, Matthew A. Gubens, Mark Hennon, Leora Horn, Rudy P. Lackner, Michael Lanuti, Ticiana A. Leal, Rogerio Lilenbaum, Jules Lin, Billy W. Loo Jr, Renato Martins, Gregory A. Otterson, Sandip P. Patel, Karen Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, James Stevenson, Scott J. Swanson, Kurt Tauer, Stephen C. Yang, Kristina Gregory, and Miranda Hughes
cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology . Arch Pathol Lab Med
Melinda Telli
addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathology complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Aliance) . J Clin
Presenter: Eric D. Hsi
We all know that non-Hodgkin lymphoma is not just one lymphoma, said Eric D. Hsi, MD, Chair of the Department of Laboratory Medicine, Professor of Pathology at Lerner College of Medicine, and member of Case Comprehensive Cancer Center
